Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia

P. Treon, Steven; Gustine, Joshua; Meid, Kirsten; Yang, Guang; Xu, Lian; Liu, Xia; Demos, Maria; Kofides, Amanda; Tsakmaklis, Nicholas; G. Chen, Jiaji; Munshi, Manit; Chan, Gloria; Dubeau, Toni; Raje, Noopur; J. Yee, Andrew; O’Donnell, Elizabeth; R. Hunter, Zachary; J. Castillo, Jorge

doi:10.1200/jco.2018.78.6426

Public

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia

Published in Journal of Clinical Oncology • Jul 25, 2018

Authors:

Steven P. Treon

Joshua Gustine

Kirsten Meid

Abstract

Purpose Ibrutinib is active in previously treated Waldenström macroglobulinemia (WM). MYD88 mutations ( MYD88 MUT ) and CXCR4 mutations ( CXCR4 MUT ) affect ibrutinib response. We report on a prospective study of ibrutinib monotherapy in symptomatic, untreated patients with WM, and the effect of CXC...

Subject

Ibrutinib

Medicine

Waldenstrom macroglobulinemia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!